0
Abstract: Slide Presentations |

SERIAL CARDIOPULMONARY EXERCISE MEASUREMENTS AND OUTCOME IN PULMONARY ARTERIAL HYPERTENSION FREE TO VIEW

Raghu Midde, MD*; Ronald Oudiz, MD; Xingguo Sun, MD; James E. Hansen, MD; Karlman Wasserman, MD, PhD
Author and Funding Information

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA


Chest


Chest. 2007;132(4_MeetingAbstracts):475. doi:10.1378/chest.132.4_MeetingAbstracts.475
Text Size: A A A
Published online

Abstract

PURPOSE: Cardiopulmonary exercise testing (CPET) can evaluate physiology and predict survival in patients with pulmonary arterial hypertension (PAH). We hypothesized that adding follow-up CPET measurements would improve prognostic ability. We examined which CPET parameters provided optimal prognostic ability in our patient population.

METHODS: To evaluate the prognostic ability of CPET in predicting death or freedom from lung transplantation, we evaluated 103 PAH patients seen in our clinic who had prospective serial CPET performed. We measured peak VO2 and evaluated receiver operating characteristics (ROC) to determine the optimal cutoff value for separating survivors from non-survivors; we then evaluated Kaplan-Meier survival curves for various survival models.

RESULTS: Patients had baseline CPET and repeat testing after 12±12 months; patients were followed for a mean of 55±29 months. Based upon ROC analysis, we selected peak VO2 <0.75 L/min as the threshold value for increased risk of death or transplantation at baseline (P=0.04). Adding follow-up peak VO2 values increased prognostic significance: the best predictor of outcome was the combination of baseline peak VO2 <0.75 L/min and worsening over time, as compared to either a baseline peak VO2 >0.75 L/min or a peak VO2 <0.75 L/min, but no worsening (P<0.0001, Figure).

CONCLUSION: Repeated CPET measurements of peak VO2 adds incremental prognostic benefit to that of single CPET measurements in patients with PAH.

CLINICAL IMPLICATIONS: In patients with PAH, presence of severe gas exchange impairment at baseline combined with worsening over time identifies patients at highest risk for poor outcome.

DISCLOSURE: Raghu Midde, Grant monies (from industry related sources) Actelion, Encysive, Gilead, Pfizer, United Therapeutics; Consultant fee, speaker bureau, advisory committee, etc. Actelion, Encysive, Gilead, Pfizer, United Therapeutics; Product/procedure/technique that is considered research and is NOT yet approved for any purpose. ambrisentan

Tuesday, October 23, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543